Clinical trials

There are many trials currently being done investigating different conditions that can be treated or improved with IMT. Scientists and doctors at Imperial are involved in many such studies currently occurring within the UK, either from the perspective of recruiting patients, and/or analysing samples from patients to better understand how IMT might provide the benefits it does. 

• FARGO (IMT for PSC):
  • https://pscsupport.org.uk/the-fargo-trial/
  • https://bmjopen.bmj.com/content/15/1/e095392.long
  • https://www.imperial.ac.uk/news/233874/new-study-explores-unique-approach-treat/
• PROMISE trial (FMT for cirrhosis):
  • https://britishlivertrust.org.uk/the-promise-study/
• DONATE study (FMT for 1st episode CDI):
  • https://www.jpiamr.eu/projects/donate/
  • https://open-research-europe.ec.europa.eu/articles/4-61
• FAITH (FMT for severe alcoholic hepatitis):
  • NIHR EME funded, in set up
• MAST (FMT prior to HCT):
  • https://www.imperial.ac.uk/metabolism-digestion-reproduction/research/digestive-diseases/hepatology--gastroenterology/mast-study/
  • https://bmjopen.bmj.com/content/14/12/e093120.long
• CATCH-IBD study (capsulised IMT in IBD):
  • Bowel Research UK

Research

There are many research groups in the UK and across the world investigating how IMT can be used to improve patients' lives. The research also delves into how gut microbiota influences overall health, exploring its role in conditions such as inflammatory bowel disease, metabolic disorders, and even mental health. By understanding these connections, scientists aim to develop new and more effective treatments that harness the power of the microbiome to benefit a wider range of patients.

Papers

Doctors and scientists working in the lab of Professor Julian Marchesi (https://profiles.imperial.ac.uk/j.marchesi/about ) at Imperial College London have been working for almost a decade in performing scientific research to investigate the fundamental mechanisms as to how IMT may work in helping people with different gut conditions and continue to lead the way in this area.

• Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome 
• The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond 
• The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases 
• The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines 
• Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans 
• Intestinal microbiota transplantation: do not forget the metabolites 
• How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection 
• Rapid resolution of COVID-19 after faecal microbiota transplantation 
• Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series 
• A multi-factorial observational study on sequential fecal microbiota transplant in patients with medically refractory Clostridioides difficile infection
• Faecal microbiota transplant in the treatment of Clostridioides difficile infection: an update 
• The use of faecal microbiota transplantation (FMT) in Europe: a Europe-wide survey 
• Inflammatory bowel disease outcomes following fecal microbiota transplantation for recurrent C. difficile infection 
• Fecal microbiota transplant mitigates adverse outcomes in patients colonized with multidrug-resistant organisms undergoing allogeneic hematopoietic cell transplantation 
• Disease prevention not decolonization – a model for fecal microbiota transplantation in patients colonized with multidrug-resistant organisms 
• Fecal microbiota transplantation: the evolving risk landscape 
• Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity 
• Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection 
• Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis 
• Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection 
• Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial derived metabolites 
• Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease 
• Effects of fecal microbiota transplantation with oral capsules in obese patients 
• Cohort study of Faecal Microbiota Transplantation for patient’s colonised with MDROs - successful prevention of invasive disease despite low decolonisation rates
• In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation 
• International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 
• Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection 
• The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications